cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer

Joohyuk Sohn(Yonsei University), Ana M. González-Angulo(The University of Texas MD Anderson Cancer Center)

Journal of Cancer

January 1, 2014

10.7150/jca.9696

Cited by 59

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

|New England Journal of Medicine|2022|2.5k

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

|Journal of Clinical Oncology|2017|1.7k

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

|The Lancet|2020|1.1k

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

|New England Journal of Medicine|2019|1k

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

|The Lancet Oncology|2018|1k